Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma

Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma is organized by i3 Health.

Dates Available:
June 1, 2023 - July 31, 2024

Description:
Presented by leading expert Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, this activity will explore guidance on current standards and new directions in newly diagnosed multiple myeloma.

Statement of Need:
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, including anti-CD38 antibodies, has provided numerous therapeutic options for newly diagnosed multiple myeloma. However, the optimal selection of induction therapy and subsequent treatment sequencing for individual patients remains a challenge. Additionally, factors including age, frailty, comorbidities, transplant eligibility, treatment-related toxicities, and supportive care needs complicate treatment decisions (Costello et al., 2022). This activity chaired by Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, will explore expert guidance on current standards and new directions in newly diagnosed multiple myeloma.

Learning Objectives:
Upon completion of this activity, participants should be able to:

• Assess guideline-recommended treatment combination and sequencing strategies in NDMM 
• Evaluate the role of minimal residual disease (MRD) assessment in NDMM treatment 
• Review the mechanism of action, efficacy, and safety of anti-CD38 monoclonal antibodies in the treatment of NDMM 
• Discuss strategies to monitor and manage treatment-related toxicities and optimize survivorship care